[A clinical evaluation of aspoxicillin in children].
Eighteen infants and children with infectious diseases were treated with aspoxicillin (ASPC), a new semisynthetic penicillin. The result was as follows: The clinical responses to ASPC were excellent in 6 patients and good in 5 patients of 11 children with bacterial infections. The bacteria isolated from the culture of throat swab and urine in 5 patients were Streptococcus pneumoniae, Escherichia coli, and Staphylococcus aureus which were all eradicated by the treatment of ASPC. The mean serum concentration of ASPC reached the peaks of 73.3 micrograms/ml in 5 cases with dose of 20 mg/kg, and 136.3 micrograms/ml in 3 cases with dose of 40 mg/kg 15 minutes after the intravenous administration. The mean half-lives of ASPC in the serum were 1.08 hours for the dose of 20 mg/kg and 1.07 hours for the dose of 40 mg/kg. The mean urinary recoveries of ASPC in 6 hours following the intravenous administration were 73.7% in 3 cases with dose of 20 mg/kg, and 79.6% in 1 case with dose of 40 mg/kg. No clinical side effect of ASPC was observed. An increase of platelet was noticed in a child with infectious mononucleosis in the course of administration of ASPC.
D000658:Amoxicillin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male
C037485:aspoxicillin; D000658:Amoxicillin